Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 221

1.

Rifaximin for treatment of hepatic encephalopathy.

Maclayton DO, Eaton-Maxwell A.

Ann Pharmacother. 2009 Jan;43(1):77-84. doi: 10.1345/aph.1K436. Epub 2008 Dec 17. Review.

PMID:
19092143
[PubMed - indexed for MEDLINE]
2.

Rifaximin for the treatment of hepatic encephalopathy.

Lawrence KR, Klee JA.

Pharmacotherapy. 2008 Aug;28(8):1019-32. doi: 10.1592/phco.28.8.1019. Review.

PMID:
18657018
[PubMed - indexed for MEDLINE]
3.

Pharmacotherapy for hepatic encephalopathy.

Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A.

Drugs. 2010 Jun 18;70(9):1131-48. doi: 10.2165/10898630-000000000-00000. Review.

PMID:
20518580
[PubMed - indexed for MEDLINE]
4.

Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.

Williams R, James OF, Warnes TW, Morgan MY.

Eur J Gastroenterol Hepatol. 2000 Feb;12(2):203-8.

PMID:
10741936
[PubMed - indexed for MEDLINE]
5.

Rifaximin: new therapeutic indication and future directions.

Rivkin A, Gim S.

Clin Ther. 2011 Jul;33(7):812-27. doi: 10.1016/j.clinthera.2011.06.007. Epub 2011 Jul 7. Review.

PMID:
21741091
[PubMed - indexed for MEDLINE]
6.

Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.

Leevy CB, Phillips JA.

Dig Dis Sci. 2007 Mar;52(3):737-41.

PMID:
17245628
[PubMed - indexed for MEDLINE]
7.

Rifaximin for the treatment of hepatic encephalopathy.

de Melo RT, Charneski L, Hilas O.

Am J Health Syst Pharm. 2008 May 1;65(9):818-22. doi: 10.2146/ajhp070298. Review.

PMID:
18436728
[PubMed - indexed for MEDLINE]
8.

Combination therapy for the treatment and prevention of hepatic encephalopathy.

Mohammad RA, Regal RE, Alaniz C.

Ann Pharmacother. 2012 Nov;46(11):1559-63. doi: 10.1345/aph.1R146. Epub 2012 Oct 23. Review.

PMID:
23092866
[PubMed - indexed for MEDLINE]
9.

Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.

Williams R, Bass N.

Rev Gastroenterol Disord. 2005;5 Suppl 1:S10-8. Review.

PMID:
15976747
[PubMed - indexed for MEDLINE]
10.

Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.

Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L.

Eur J Gastroenterol Hepatol. 2008 Nov;20(11):1064-70. doi: 10.1097/MEG.0b013e328302f470. Review.

PMID:
19047837
[PubMed - indexed for MEDLINE]
11.

The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.

Huang E, Esrailian E, Spiegel BM.

Aliment Pharmacol Ther. 2007 Oct 15;26(8):1147-61.

PMID:
17894657
[PubMed - indexed for MEDLINE]
Free Article
12.

Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, Pardo A; Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group.

J Hepatol. 2003 Jan;38(1):51-8.

PMID:
12480560
[PubMed - indexed for MEDLINE]
13.

Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.

Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM.

Yonsei Med J. 2005 Jun 30;46(3):399-407.

PMID:
15988813
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Rifaximin for the treatment of hepatic encephalopathy.

Mullen K, Prakash R.

Expert Rev Gastroenterol Hepatol. 2010 Dec;4(6):665-77. doi: 10.1586/egh.10.78. Erratum in: Expert Rev Gastroenterol Hepatol. 2011 Feb;5(1):133-4.

PMID:
21108586
[PubMed - indexed for MEDLINE]
15.

A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK.

Am J Gastroenterol. 2013 Sep;108(9):1458-63. doi: 10.1038/ajg.2013.219. Epub 2013 Jul 23.

PMID:
23877348
[PubMed - indexed for MEDLINE]
16.

Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.

Irimia R, Trifan A.

Rev Med Chir Soc Med Nat Iasi. 2012 Oct-Dec;116(4):1021-7.

PMID:
23700882
[PubMed - indexed for MEDLINE]
17.

Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.

Neff GW, Kemmer N, Zacharias VC, Kaiser T, Duncan C, McHenry R, Jonas M, Novick D, Williamson C, Hess K, Thomas M, Buell J.

Transplant Proc. 2006 Dec;38(10):3552-5.

PMID:
17175328
[PubMed - indexed for MEDLINE]
18.

Durability of rifaximin response in hepatic encephalopathy.

Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N.

J Clin Gastroenterol. 2012 Feb;46(2):168-71. doi: 10.1097/MCG.0b013e318231faae.

PMID:
22011586
[PubMed - indexed for MEDLINE]
19.

Management of hepatic encephalopathy in the hospital.

Leise MD, Poterucha JJ, Kamath PS, Kim WR.

Mayo Clin Proc. 2014 Feb;89(2):241-53. doi: 10.1016/j.mayocp.2013.11.009. Epub 2014 Jan 8. Review.

PMID:
24411831
[PubMed - indexed for MEDLINE]
20.

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.

Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP.

Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. doi: 10.1111/j.1365-2036.2011.04808.x. Epub 2011 Aug 17.

PMID:
21848797
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk